Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

BACKGROUND: The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. METHODS: We present t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Cortellini, Alessio, Ricciuti, Biagio, Tiseo, Marcello, Bria, Emilio, Banna, Giuseppe L, Aerts, Joachim GJV, Barbieri, Fausto, Giusti, Raffaele, Cortinovis, Diego L, Migliorino, Maria R, Catino, Annamaria, Passiglia, Francesco, Torniai, Mariangela, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Di Noia, Vincenzo, Signorelli, Diego, Gelibter, Alain, Occhipinti, Mario Alberto, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Inno, Alessandro, De Tursi, Michele, Di Marino, Pietro, Mansueto, Giovanni, Zoratto, Federica, Grossi, Francesco, Filetti, Marco, Pizzutilo, Pamela, Russano, Marco, Citarella, Fabrizio, Cantini, Luca, Targato, Giada, Nigro, Olga, Ferrara, Miriam G, Buti, Sebastiano, Scodes, Simona, Landi, Lorenza, Guaitoli, Giorgia, Della Gravara, Luigi, Tabbò, Fabrizio, Ricciardi, Serena, De Toma, Alessandro, Friedlaender, Alex, Petrelli, Fausto, Addeo, Alfredo, Porzio, Giampiero, Ficorella, Corrado
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Clinical/Translational Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574933/
https://ncbi.nlm.nih.gov/pubmed/33077515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001403
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky